Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
APREDOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York.
Apreo Health Announces First Patient Treated in BREATHE-3, Pivotal Clinical Trial of Company’s BREATHE Airway Scaffold
APREMENLO PARK, Calif.--(BUSINESS WIRE)--Apreo Health, a clinical-stage medical device company pioneering a novel, tissue-sparing approach for treating severe emphysema, today announced that the first patient has been treated in its pivotal clinical trial, BREATHE-3 (Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung—Study 3). The trial is evaluating the safety and efficacy of the Apreo BREATHE Airway Scaffold, a bronchoscopically delivered, self-expanding implant designed to
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
APREEarly evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor, APR-1051
Aprea Therapeutics Q1 EPS $(0.66) Up From $(0.67) YoY, Sales $162.46K Down From $380.57K YoY
APREAprea Therapeutics Reports Dosing of Patient With HPV+ Head And Neck Squamous Cell Carcinoma In Ongoing ACESOT-1051 Trial
APREAprea Therapeutics Q4 EPS ($0.49) Up From ($0.92) YoY.
APREAprea Therapeutics Enters Medical Transfer Agreement With MD Anderson Cancer Center To Explore APR-105 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma
APREHC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
APREHC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
APRE